Attention is focusing on whether another company will release an Avastin (Bevacizumab) biosimilar approved by Samsung Bioepis and Pfizer.

This is because it was found that a new item was approved by the MFDS in August. If the item is approved, a total of four items, including the original Avastin by Roche and three biosimilars, are expected to compete. According to the MFDS on the 24th, a new biosimilar with Bevacizumab, the same ingredient as Avastin, was applied on August 30.

The item was found to have applied for permission, excluding ovarian cancer-related indications that could cause patent disputes. Samsung Bioepis' Onbevezy and Pfizer's Jairabeve were also approved except for some